Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first‐line chemotherapy in patients with advanced non‐small cell lung cancer

Autor: Xi Wang, Ligong Nie, Zhanwei Hu, Ying Liu, Zhe Jin, Yuan Cheng
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
Lung Neoplasms
medicine.medical_treatment
NSCLC
Gastroenterology
0302 clinical medicine
Quality of life
Carcinoma
Non-Small-Cell Lung
Antineoplastic Combined Chemotherapy Protocols
Infusions
Intravenous
Endostar
General Medicine
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Recombinant Proteins
Endostatins
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
Original Article
Female
Non small cell
First line chemotherapy
Adult
Pulmonary and Respiratory Medicine
medicine.medical_specialty
lcsh:RC254-282
Drug Administration Schedule
03 medical and health sciences
Drug Therapy
Internal medicine
medicine
Humans
In patient
Lung cancer
Adverse effect
Aged
Retrospective Studies
Chemotherapy
Continuous intravenous infusion
business.industry
Significant difference
Original Articles
medicine.disease
Survival Analysis
030104 developmental biology
Quality of Life
Patient Compliance
business
Zdroj: Thoracic Cancer, Vol 10, Iss 7, Pp 1576-1580 (2019)
Thoracic Cancer
ISSN: 1759-7706
1759-7714
Popis: Background Intravenous infusion of Endostar for three to four hours per day for 14 days reduces patient compliance and affects quality of life. Continuous intravenous infusion (CI) represents a novel method of administration; however, it is unclear whether it is effective and safe when compared to the traditional method. Methods We retrospectively reviewed patients with advanced non-small cell lung cancer (NSCLC) administered CI (20 patients) or intermittent intravenous infusion (II, 49 patients) of Endostar combined with first-line chemotherapy. Three patients in the II group discontinued therapy because of adverse effects. Results Median progression-free survival was 6.0 months in the CI group and 3.8 months in the II group, with no significant difference (P = 0.1). The objective response and disease control rates were also similar in the CI and II groups (40.0 vs. 32.6%, P = 0.562; 65 vs. 69.6%, P = 0.714, respectively). Conclusion CI of Endostar combined with first-line chemotherapy for advanced NSCLC had similar progression-free survival, objective response, and overall response rates as II, with tolerable adverse effects.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje